Results 1 to 10 of about 373,830 (191)
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Biomarker Research, 2019 Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Yuping Gong
doaj +2 more sources
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Frontiers in Oncology, 2019 The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub +13 more
doaj +2 more sources
Isocitrate dehydrogenase mutations in gliomas. [PDF]
Neuro-Oncology, 2016 Over the last decade, extraordinary progress has been made in elucidating the underlying genetic causes of gliomas. In 2008, our understanding of glioma genetics was revolutionized when mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) were identified in the vast majority of progressive gliomas and secondary glioblastomas (GBMs).
Matthew S. Waitkus, B. Diplas, Hai Yan
semanticscholar +3 more sources
Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH). [PDF]
PLoS Genetics, 2017 DJ-1 is one of the causative genes for early onset familiar Parkinson's disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Jinsung Yang +11 more
doaj +2 more sources
Isocitrate dehydrogenase mutations in myeloid malignancies [PDF]
Leukemia, 2016 Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients ...
B. Medeiros +5 more
semanticscholar +4 more sources
Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside [PDF]
PharmaceuticalsIsocitrate dehydrogenase (IDH) mutant gliomas are a primary malignancy of the central nervous system (CNS) malignancies, most commonly affecting adults under the age of 55.
Merve Hazal Ser +3 more
doaj +2 more sources
Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification [PDF]
Journal of Clinical and Diagnostic Research, 2023 Introduction: The 2016 World Health Organisation (WHO) classification of tumours of the Central Nervous System (WHO CNS 2016 classification) is used to classify diffuse gliomas as astrocytoma, Oligodendroglioma (ODG), glioblastoma which are three ...
Lokesh Kumar +3 more
doaj +1 more source
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Cell Reports Medicine, 2021 Summary The most frequently mutated metabolic genes in human cancer are those encoding the enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been identified in more than 20 tumor types.
Ingvild Hvinden +3 more
semanticscholar +1 more source
Cancers, 2022 Simple Summary While isocitrate dehydrogenases have been known for decades, their mechanisms in tumors are gradually becoming clearer. The three isocitrate dehydrogenase isoforms in human cells differ in their subcellular localization, molecular ...
Q. He +3 more
semanticscholar +1 more source